Atopic Dermatitis
1,104
127
177
659
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
249 trials with published results (23%)
Research Maturity
659 completed trials (60% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.4%
82 terminated out of 1104 trials
88.9%
+2.3% vs benchmark
23%
253 trials in Phase 3/4
38%
249 of 659 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 659 completed trials
Clinical Trials (1104)
Natural History and Genetics of Food Allergy and Related Conditions
Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes
Retention of Vernix Caseosa in Newborns for Primary Prevention of Atopic Dermatitis
A Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic Dermatitis
Abrocitinib Dose Tapering in Patients With Atopic Dermatitis
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)
Oral Melatonin as Adjunctive Therapy in Adults With Atopic Dermatitis
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis
Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis